Trial Profile
An extension trial of emricasan in patients with cirrhosis and severe portal hypertension
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Liver cirrhosis; Portal hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ENCORE-XT
- Sponsors Conatus Pharmaceuticals; Histogen
- 05 Dec 2018 According to a Conatus Pharmaceuticals media release, data from this trial is expected in mid-2019.
- 19 Nov 2015 New trial record